Aytu BioPharma, Inc. AYTU 深 滬
已收盤 06-12 16:00:00 美东时间
2.15
-0.040
-1.83%
華盛通- 最 高2.22
- 今 開2.192
- 成交量 1.44万股
- 最 低 2.15
- 昨 收 2.19
- 總市值 2307.64万
- 52周最高 3.065
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 1.6501
- 委 比 88.26%
- 總股本 1073.32万
- 歷史最高 12920.00
- 量 比 0.48
- 振 幅 3.20%
- 歷史最低 0.95
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $14.5
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ:AYTU) with a Buy and raises the price target from $14 to $14.5.
06-11 17:44
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call
Aytu BioPharma (NASDAQ:AYTU) released third-quarter financial results and hoste...
05-14 05:39
Aytu BioPharma Q3 EPS $(0.53) Misses $(0.51) Estimate, Sales $12.411M Beat $12.053M Estimate
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.51) by 3.92 percent. This is a 352.38 percent decrease over earnings of $0.21 per share from
05-14 04:07
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Aytu BioPharma Q2 Earnings Report: What Investors Need to Know
The earnings results for Aytu BioPharma (NASDAQ:AYTU) for Q2 were made public o...
02-04 05:58
Aytu BioPharma Q2 revenue beats expectations
Aytu BioPharma Q2 revenue beats expectations Overview Pharmaceutical company's Q2 revenue beat analyst expectations Adjusted EBITDA for Q2 beat analyst expectations Outlook Company did not provide specific financial guidance for future quarters or full year in press release Result Drivers SHIFT IN M
02-04 05:21
Earnings Summary: Aytu BioPharma Q2
Aytu BioPharma (NASDAQ:AYTU) released its Q2 earnings on Tuesday, February 3, 2...
02-04 05:08
Aytu Biopharma meldet für das zweite Quartal (Q2) 2026 einen Nettoverlust von USD 10,58 Mio. und einen Rückgang des bereinigten EBITDA um 163 Prozent auf USD -0,80 Mio
Aytu Biopharma meldet für das zweite Quartal (Q2) 2026 einen Nettoverlust von USD 10,58 Mio. und einen Rückgang des bereinigten EBITDA um 163 Prozent auf USD -0,80 Mio Aytu Biopharma Inc. hat die Finanzergebnisse für das zweite Quartal des Geschäftsjahres 2026 veröffentlicht. Der Gesamtumsatz belief
02-04 05:06
Earnings Scheduled For February 3, 2026
Companies Reporting Before The Bell • Atkore (NYSE:ATKR) is expected to report ...
02-03 19:11
